Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

NCT02721888 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

127

Enrollment

OTHER

Sponsor class

Stopped Failure of inclusion

Conditions

Type 2 Diabetes

Interventions

DRUG: Liraglutide
DRUG: MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
BIOLOGICAL: Blood sample
OTHER: Kinetic substudy (10 patients)

Sponsor

Centre Hospitalier Universitaire Dijon